Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH

Traders Union
All News
Companies
Amylyx wraps PBH trial enrollment

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Market Voices

Companies

24.03.2026

Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH — Amylyx wraps PBH trial enrollment

Amylyx Pharmaceuticals announced the completion of patient enrollment for its pivotal Phase 3 LUCIDITY clinical trial targeting post-bariatric hypoglycemia (PBH).

The company expressed gratitude to trial sites and participants, noting that topline data are expected in the third quarter of 2026. The LUCIDITY trial represents a significant step in advancing potential therapies for PBH, a challenging complication following bariatric surgery.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Amylyx Pharmaceuticals has recently undertaken a major hiring push as it seeks to build momentum in areas of unmet medical need, according to a company update. The workforce expansion comes as Amylyx advances its pipeline in rare and challenging conditions. The company continues to develop therapies for complex post-surgical complications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Proof of Reserves: the new standard for cryptocurrency exchanges

By Pavlo Kot
19 hours ago

Proof of Reserves: the new standard for cryptocurrency exchanges

Editors' Picks

Three trends that could reshape the crypto market over the next decade

By Eugene Komchuk
Yesterday

Three trends that could reshape the crypto market over the next decade

Editors' Picks

Trump financial disclosure: How the president's crypto income became a U.S. ethics issue

By Oleg Tkachenko
02.07.2026

Trump financial disclosure: How the president's crypto income became a U.S. ethics issue

Editors' Picks

All Editors' Top Picks

Latest Amylyx News

Amylyx Pharmaceuticals expands team to address urgent healthcare challenges

By Igor Krasulya
17.03.2026

Amylyx Pharmaceuticals expands team to address urgent healthcare challenges

Companies

Amylyx Pharmaceuticals pushes for novel therapy development

By Olesia Kramarenko
06.01.2026

Amylyx Pharmaceuticals pushes for novel therapy development

Market Voices

Amylyx Pharmaceuticals reveals promising results from Wolfram syndrome trial

By Eugene Komchuk
13.11.2025

Amylyx Pharmaceuticals reveals promising results from Wolfram syndrome trial

Market Voices

All Amylyx News

Pavlo Kot
19 hours ago

Proof of Reserves: the new standard for cryptocurrency exchanges

Eugene Komchuk
Yesterday

Three trends that could reshape the crypto market over the next decade

Oleg Tkachenko
02.07.2026

Trump financial disclosure: How the president's crypto income became a U.S. ethics issue

Pavlo Kot
01.07.2026

Code red: What's behind Bitcoin’s sharp selloff?

Anastasiia Chabaniuk
01.07.2026

MiCA is live: How EU new rules are changing crypto market

Ashutosh Sureka
3 hours ago

Korean chip ETFs exceed $19 billion in exposure, Mario Nawfal warns

Yaroslav Dmytrenko
4 hours ago

Bitfinex whale ETH longs surge, Carl Runefelt notes

Hanna Syniavska
4 hours ago

Gary Vaynerchuk: Offering free Veefriends NFT to dedicated collectors

Daria Chernytska
4 hours ago

Alex Svanevik: Protocols should mirror deals for tokenholder participation

Parshwa Turakhiya
5 hours ago

Anthony Pompliano: Encourages self-managed investment portfolios with AI technology

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Pavlo Kot
19 hours ago

Proof of Reserves: the new standard for cryptocurrency exchanges

Proof of Reserves: the new standard for cryptocurrency exchanges

Parshwa Turakhiya
Yesterday

Bitcoin pushes toward $62,000 as risk appetite returns

Bitcoin pushes toward $62,000 as risk appetite returns

Ivan Andriyenko
Yesterday

EU-U.S. trade boom leaves German carmakers behind

EU-U.S. trade boom leaves German carmakers behind

Eugene Komchuk
Yesterday

Christine Lagarde may leave ECB earlier than expected

Christine Lagarde may leave ECB earlier than expected

Jose Antonio Gastelum
Yesterday

Brazil sets tougher standards for crypto service providers

Brazil sets tougher standards for crypto service providers

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Microsoft rebounds as AI confidence improves after sharp correction

Anton Kharitonov
Now

Alphabet extends recovery as AI optimism offsets macro uncertainty

Mykhailo Ihnatenko
Now

Defense spending pushes Rolls-Royce shares toward record highs

Anton Kharitonov
Now

Bitcoin rebounds as softer U.S. jobs data lifts risk appetite

Anton Kharitonov
Now

WTI stays under pressure as weak U.S. jobs data adds demand risk

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.